# Audit Report: US FDA Label Update (Rituxan)

## ğŸ“‚ Data Provenance & Integrity (United States)
This document serves as the regulatory baseline for Rituxan's dosage and administration standards.

- **Source Agency:** U.S. Food and Drug Administration (FDA)
- **Document Type:** Prescribing Information (Label Update)
- **Drug Name:** RITUXAN (rituximab)
- **SHA-256 Hash:** `29D83DF7AE7F22ADE9E2431511399FA99EABC84D7F01983B1E705097D25D1562`
- **Revision Date:** October 2012

---

## ğŸ” Key Regulatory Data
- **Initial U.S. Approval:** 1997
- **Dosage Forms & Strengths:** 100 mg/10 mL and 500 mg/50 mL single-use vials.
- **Major Changes (Oct 2012):** Updated sections on Dosage and Administration (2.1) and Recommended Concomitant Medications (2.7).

---

## ğŸ“Š Audit Comparison Baseline
This 2012 FDA data is used to calculate the administrative lag in other regions:
- **Japan (MHLW):** The 100mg/500mg dosage variations were still under deliberation in Jan 2026.
- **Estimated Lag:** **~13.2 Years** (Compared to this 2012 baseline).

---
*This document is part of the **OncoAudit (v2.0.0)** research series.*
